Treatment of Acute Migraine Attack With Diclofenac Sodium: A Double-Blind Study

1992 ◽  
Vol 32 (2) ◽  
pp. 98-100 ◽  
Author(s):  
George N. Karachalios ◽  
Adroniki Fotiadou ◽  
Nickolaos Chrisikos ◽  
Alexandros Karabetsos ◽  
Kyriakos Kehagioglou
Keyword(s):  
Migraine Attack ◽  
Diclofenac Sodium ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Acute Migraine Attack

Differences of Anti-Nociceptive Mechanisms of Migraine Drugs on the Trigeminal Pain Processing during and Outside Acute Migraine Attacks

Cephalalgia ◽  
2004 ◽  
Vol 24 (8) ◽  
pp. 657-662 ◽  
Author(s):  
Z Katsarava ◽  
V Limmroth ◽  
O Baykal ◽  
D Akguen ◽  
H-C Diener ◽  
...  
Keyword(s):  
Migraine Attack ◽  
Healthy Subjects ◽  
Blink Reflex ◽  
Acute Attack ◽  
Pain Processing ◽  
Acute Migraine ◽  
Double Blind ◽  
Nociceptive Blink Reflex ◽  
Nociceptive Processing ◽  
Acute Migraine Attack

The aim of this study was to investigate central anti-nociceptive mechanisms of i.v. acetylsalicylic acid (ASA) and oral zolmitriptan (ZOL) in migraine patients and healthy subjects using the ‘nociceptive’ blink reflex (nBR). Twenty-eight migraine patients received ASA ( n = 14, 1000 mg i.v) or ZOL ( n = 14, 5 mg p.o) during the acute migraine attack and interictally. Thirty healthy subjects received either ASA or ZOL vs. placebo using a double blind cross over design. nBR was recorded in all patients and subjects before, 60 and 90 min after treatment. ASA and ZOL did not inhibit nBR responses in healthy subjects. Both ASA and ZOL suppressed nBR responses (ASA by 68%, ZOL by 78%) only during the acute attack but not interictally. The data suggest, that the anti-nociceptive effects of migraine drugs on the trigeminal nociceptive processing are different during and outside an acute migraine attack.

Treatment of Acute Migraine Attack: Naproxen and Placebo Compared

Cephalalgia ◽  
1985 ◽  
Vol 5 (2) ◽  
pp. 115-119 ◽  
Author(s):  
Knut Nestvold ◽  
Reidar Kloster ◽  
Markku Partinen ◽  
Raimo Sulkava
Keyword(s):  
Migraine Attack ◽  
Randomized Study ◽  
Treatment Preferences ◽  
Acute Migraine ◽  
Treatment Results ◽  
Double Blind ◽  
Head Pain ◽  
Main Complaint ◽  
Gastrointestinal Discomfort ◽  
Acute Migraine Attack

A double-blind, cross-over, randomized study of acute migraine attack compared treatment results of naproxen with that of placebo. Each treatment period continued for either three months or six migraine attacks, whichever occurred first. The initial dose of naproxen was 750 mg, with additional 250–500 mg doses taken if and when required, to a maximum of five 250 mg tablets within a period of 24 h in each migraine attack. Forty-one patients were enrolled in the study; they had all experienced at least two but not more than eight migraine attacks a month during the preceding year. Thirty-two patients completed the two treatment periods. Naproxen was statistically significantly superior to placebo in reducing the severity of head pain, nausea, and photophobia; in shortening the duration of head pain, nausea, vomiting, photophobia, and lightheadedness; in diminishing the frequency of vomiting; and in decreasing the need for escape medication. Both patient and physician treatment preferences significantly favoured naproxen. Nine side effects were experienced by seven patients while receiving placebo and seven by five patients during naproxen treatment. Mild gastrointestinal discomfort was the main complaint. Only one patient withdrew from treatment because of a side effect, which occurred while receiving placebo.

Double-Blind Comparison of An Acetaminophen 400 mg-Codeine 25 mg Combination Versus Aspirin 1000 mg and Placebo in Acute Migraine Attack

Cephalalgia ◽  
1994 ◽  
Vol 14 (2) ◽  
pp. 156-161 ◽  
Author(s):  
F Boureau ◽  
JM Joubert ◽  
V Lasserre ◽  
B Prum ◽  
G Delecoeuillerie
Keyword(s):  
Clinical Trials ◽  
Migraine Attack ◽  
Evaluation Criteria ◽  
Complete Disappearance ◽  
Acute Migraine ◽  
Double Blind ◽  
Significant Difference ◽  
The Difference ◽  
Blind Comparison ◽  
Acute Migraine Attack

The purpose of this study was to compare the efficacy and tolerance of a single dose of the acetaminophen 400 mg-codeine 25 mg combination (ACC) aspirin 1000 mg (A) and a placebo (P) for the treatment of acute migraine attack. The study design was randomized, multicentre, double-blind and double dummy with cross-over on three periods. Of the 198 patients who had three attacks 29.8%, 52.3% and 49.7% had recorded the complete or almost complete disappearance of the pain at 2 h after P, A and ACC respectively. When compared with the placebo, the difference was significant for the A and ACC. When complete disappearance of pain at 2 h was used as a criterion, no significant difference was observed. These results enabled the sensitivity of the evaluation criteria suggested for clinical trials of migraine attack to be discussed.

Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study

2021 ◽  
Author(s):  
Sultan Tuna Akgol Gur ◽  
Elif Oral Ahiskalioglu ◽  
Muhammed Enes Aydin ◽  
Abdullah Osman Kocak ◽  
Pelin Aydin ◽  
...  
Keyword(s):  
Migraine Attack ◽  
Blind Study ◽  
Double Blind Study ◽  
Intravenous Lidocaine ◽  
Double Blind

Flunarizine (10 and 20 mg) i.v. Versus Placebo in the Treatment of Acute Migraine Attacks: A Multi-Centre Double-Blind Study

Cephalalgia ◽  
1990 ◽  
Vol 10 (2) ◽  
pp. 77-81 ◽  
Author(s):  
Volker Pfaffenrath ◽  
Wolfgang Oestreich ◽  
Wolfgang Haase
Keyword(s):  
Blood Pressure ◽  
Visual Analogue Scale ◽  
Drug Administration ◽  
Analogue Scale ◽  
Blind Study ◽  
Response To Treatment ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Suitable Alternative

In a multi-centre, randomized double-blind study, the effect and tolerance of 10 and 20 mg flunarizine i.v. versus placebo was tested on 102 migraineurs with acute migraine attacks with and/or without aura. Thirty-seven patients received 10 mg flunarizine, 32 received 20 mg and 33 received placebo. The groups were comparable. Response to treatment was defined as pain reduction of at least 50% within 60 min on a visual analogue scale after i.v. drug administration. This effect was noted on 59.4% with 20 mg flunarizine, on 24.3% with 10 mg flunarizine and on 30.3% with placebo. The tolerance of flunarizine i.v. was similar to placebo. Blood pressure and pulse rate were not affected by flunarizine. All in all, 20 mg flunarizine i.v. appeared to be a suitable alternative for treatment of acute migraine attacks.

scholarly journals Bioequivalence of Two Prolonged-Release Diclofenac Sodium Formulations in Healthy Volunteers: A Randomized, Crossover, Double-Blind Study

2017 ◽  
Vol 09 (06) ◽  
Author(s):  
Gonzalez Delgado CA ◽  
Padron Yaquis AS ◽  
Jimenez Rodriguez D ◽  
Cazanave Guarnaluce D ◽  
Alejo Cisneros PL ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Diclofenac Sodium ◽  
Blind Study ◽  
Prolonged Release ◽  
Double Blind Study ◽  
Double Blind

A Double-Blind Study of Ibuprofen Versus Placebo in the Treatment of Acute Migraine Attacks

Cephalalgia ◽  
1992 ◽  
Vol 12 (3) ◽  
pp. 169-171 ◽  
Author(s):  
Reidar Kloster ◽  
Knut Nestvold ◽  
Steinar T Vilming
Keyword(s):  
Side Effects ◽  
Initial Dose ◽  
Acute Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inflammatory Drug ◽  
Anti Inflammatory

The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine. Twenty-five patients completed a double-blind placebo-controlled multicrossover trial. The initial dose of ibuprofen was 1200 mg. Six migraine attacks were randomly treated in each patient, three with ibuprofen and three with placebo. The results indicated a statistically significant reduction in the duration of the migraine attacks and also a statistically significant reduction in the severity of headache and nausea in the ibuprofen-treated attacks. The use of additional medication was significantly reduced in the ibuprofen-treated attacks (25.6% vs 57.5%), No serious side effects were reported. Ibuprofen is valuable in the treatment of acute migraine attacks.

Sign in / Sign up

Export Citation Format

Share Document